... REYKJAVIK Iceland Oct. 11 /- deCODE genet... With the launch of deCODE MI we have taken another of ourbreakthrou...How to order deCODE MI(TM) ...deCODE MI(TM) is performed in deCODE's Clinical Laboratory Improvement...

REYKJAVIK, Iceland, Oct. 11 /PRNewswire-FirstCall/ -- deCODE genetics
(Nasdaq: DCGN) today announced the launch of deCODE MI(TM), a reference
laboratory test for variations in the genome (called SNPs) that the company
has associated with increased risk of myocardial infarction, or heart
attack. The SNPs are located on chromosome 9 and were discovered by deCODE
earlier this year. As described in the journal Science in July, deCODE
scientists found that people who carry two copies of these variants are at
double the risk of suffering an early heart attack -- before the age of 50
in men and 60 in women -- than are those who do not carry them. deCODE
validated the role of these variants in five groups of patients and
controls from Iceland and the United States, and other researchers have
replicated this finding in several European, US, and Canadian cohorts.

"With the launch of deCODE MI, we have taken another of our
breakthroughs in genetics and transformed it into a new tool in the fight
to prevent heart attack. While many risk factors for heart attack are
understood, the disease remains the leading cause of death in the
industrialized world and the early- onset cases often take both patients
and doctors so dangerously by surprise. deCODE MI(TM) tests for a genetic
risk factor that is independent of other risks such as cholesterol, obesity
and smoking, and therefore provides a means of identifying individuals who
may derive particular benefit from earlier and more aggressive prevention
efforts," said Dr. Kari Stefansson, CEO of deCODE.

How to order deCODE MI(TM)

deCODE MI(TM) is performed in deCODE's Clinical Laboratory Improvement
Amendments (CLIA) certified laboratory, and must be authorized by a
qualified physician. If you are an individual who would like more
information on deCODE MI(TM) to discuss with your doctor, or a physician
interested in learning more about deCODE MI(TM) for your patients, please
visit us at http://www.decodediagnostics.com.

The variants detected by deCODE MI(TM), are two SNPs (single-letter
variants in the genome) on chromosome 9p21. They were discovered by deCODE
scientists earlier this year through genome-wide SNP analysis in Iceland
and replicated in three cohorts of European descent from Philadelphia,
Atlanta and Durham, North Carolina. Of the 17,000 patients and control
subjects in the study, more than 20% of participants carried two copies of
the variant, corresponding to a more than 60% increase in risk of heart
attack, regardless of age of onset, compared to those without the variant.
In early-onset cases -- men and women who suffered a heart attack before
the ages of 50 and 60, respectively -- carrying two copies of the variant
corresponds to an approximate doubling of risk compared to non-carriers.
The variant is estimated to account for approximately one-fifth of the
incidence of heart attack in populations of European origin, and nearly one
third of early-onset cases, making it the one of the most significant
genetic risk factors found to date for heart attack as a public health
problem.

About deCODE

deCODE is a biopharmaceutical company applying its discoveries in human
genetics to the development of drugs and diagnostics for common diseases.
deCODE is a global leader in gene discovery -- our population approach and
resources have enabled us to isolate key genes contributing to major public
health challenges from cardiovascular disease to cancer, genes that are
providing us with drug targets rooted in the basic biology of disease.
Through its CLIA-certified laboratory, deCODE is offering a growing range
of DNA-based tests for gauging risk and empowering prevention of common
diseases, including deCODE T2(TM) in type 2 diabetes; deCODE AF(TM) for
atrial fibrillation and stroke; and deCODE MI(TM) for heart attack. deCODE
is delivering on the promise of the new genetics(SM). On the web at
http://www.decode.com.

Any statements contained in this presentation that relate to future
plans, events or performance are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially from
those described in the forward- looking statements. These risks and
uncertainties include, among others, those relating to technology and
product development, integration of acquired businesses, market acceptance,
government regulation and regulatory approval processes, intellectual
property rights and litigation, dependence on collaborative relationships,
ability to obtain financing, competitive products, industry trends and
other risks identified in deCODE's filings with the Securities and Exchange
Commission. deCODE undertakes no obligation to update or alter these
forward-looking statements as a result of new information, future events or
otherwise.

(Date:12/8/2016)... , Dec. 8, 2016 Eli Lilly and ... results of its phase 3 EXPEDITION3 trial at the ... meeting. As previously disclosed, solanezumab did not meet the ... of solanezumab initiated in people with mild dementia due ... regulatory submissions for solanezumab for the treatment of mild ...

(Date:12/8/2016)... Pa. , Dec. 8, 2016 Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...

(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...

(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...

(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...

(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...